Dr. Quezada earned an undergraduate degree in biochemistry from the P. Universidad Católica de Chile and a Ph.D. from Dartmouth Medical School, where his research focused on the mechanisms for the induction of transplantation tolerance.  Working with Dr. Randy Noelle at Dartmouth, Dr. Quezada developed a model to study anti-CD154 graft tolerance and made several fundamental contributions to the understanding of the immune regulation and mechanisms of transplantation rejection and tolerance.

In 2004, Dr. Quezada joined the laboratory of Dr. James Allison at Memorial Sloan-Kettering Cancer Center, where he has carried out postdoctoral research aimed at understanding the mechanisms governing anti-tumor T-cell immunity and how these mechanisms can be manipulated for the generation of potent anti-tumor immune responses.  In November 2011, Dr. Quezada joined the University College London Cancer Institute in the United Kingdom as head of the Immune Regulation and Tumor Immunotherapy group.

A Cancer Research Institute fellow from 2005 to 2008, Dr. Quezada has also been the recipient of a John W. Strohbern Medal, the Sunny-Plattsburgh Basic Science Research Fellowship, and, most recently, the CRUK Career Development Fellowship. Since 2006, Dr. Quezada has been a young investigator member of the Millennium Nucleus on Immunology and Immunotherapy of the Chilean Ministry of Planning and has served as an external evaluator for the Chilean National Science and Technology Research Fund.

Additional information on Sergio Quezada’s work on Immune Regulation and Tumour Immunotherapy can be found at his website.